In this latest rapid-reference memory aid from Diabetes & Primary Care, Pam Brown summarises the doses, indications and licences of the SGLT2 inhibitor class of diabetes drugs in adults.
Update history
19 October 2023: Updated to reflect changes in licensing for empagliflozin.
Some of the known excess risk of type 2 diabetes in people with heart failure attenuated, and outcomes improved.
22 Jan 2025